SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

PRODUCT INFORMATION

GSK547

Item No. 37347

CAS Registry No.:	2226735-55-1
Formal Name:	6-[4-[[(5S)-5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl]carbonyl]-1-piperidinyl]-4-pyrimidinecarbonitrile
Synonym:	RIP1i
MF:	$C_{20}H_{18}F_2N_6O$
FW:	396.4
Purity:	≥98%
UV/Vis.:	λ_{max}: 256 nm
Supplied as:	A solid
Storage:	-20°C
Stability:	≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

GSK547 is supplied as a solid. A stock solution may be made by dissolving the GSK547 in the solvent of choice, which should be purged with an inert gas. GSK547 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of GSK547 in DMF is approximately 1 mg/ml. GSK547 is slightly soluble in ethanol and DMSO.

Description

GSK547 is an inhibitor of receptor-interacting serine/threonine kinase 1 (RIPK1; IC_{50} = 31 nM).[1] It is selective for RIPK1 over a panel of 371 kinases, including RIPK2, -3, -4, and -5, at 10 µM. *In vivo*, GSK547 (100 mg/kg) increases survival and reduces tumor volume and the number of liver metastases in a *P48*^{Cre} *Kras*^{G12D} orthotopic mouse model of progressive pancreatic ductal adenocarcinoma (PDA). Adoptive transfer of tumor-infiltrating T cells isolated from GSK547-treated mice protects against orthotopic PDA tumor growth in mice. GSK547 also reduces plasma levels of TNF-α and IL-1β and decreases macrophage infiltration in aortic sinus lesions in an *ApoE*$^{SA/SA}$ mouse model of early-phase atherogenesis.[2]

References

1. Wang, W., Marinis, J.M., Beal, A.M., *et al.* RIP1 kinase drives macrophage-mediated adaptive immune tolerance in pancreatic cancer. *Cancer Cell* **34(5)**, 757-774 (2018).
2. Zhang, Y., Li, H., Huang, Y., *et al.* Stage-dependent impact of RIPK1 inhibition on atherogenesis: Dual effects on inflammation and foam cell dynamics. *Front. Cardiovasc. Med.* **8:715337**, (2021).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM